Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 févr. 2018 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine to Present at 2018 BIO CEO & Investor Conference

HALIFAX, Nova Scotia, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced it will participate in this year’s BIO...
31 janv. 2018 07h05 HE | Source: Immunovaccine Inc.

Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression

HALIFAX, Nova Scotia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced the publication of a preclinical study...
24 janv. 2018 08h00 HE | Source: Immunovaccine Inc.

Immunovaccine Named to 2018 OTCQX Best 50

HALIFAX, Nova Scotia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has been named to the 2018...
18 janv. 2018 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine Names Joseph Sullivan, Experienced Global Pharmaceutical and Vaccine Executive, as Senior Vice President, Business Development

HALIFAX, Nova Scotia, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has appointed Joseph Sullivan to...
03 janv. 2018 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine to Present at 2018 Biotech Showcase™ Conference

HALIFAX, Nova Scotia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in...
07 déc. 2017 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic

HALIFAX, Nova Scotia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company, today...
05 déc. 2017 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

Data From First Dosing Cohort Show a 70% Disease Control Rate – Including 30% of Patients with Partial Responses – and Demonstrate a Tolerable Safety Profile Immunovaccine to Host a Conference Call...
04 déc. 2017 17h05 HE | Source: Immunovaccine Inc.

Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

HALIFAX, Nova Scotia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it will hold a webcast and...
21 nov. 2017 07h05 HE | Source: Immunovaccine Inc.

Immunovaccine and Leidos Expand Collaboration to Develop Malaria Vaccines Formulated in DepoVax™

HALIFAX, Nova Scotia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company, today announced that it is expanding its...
13 nov. 2017 07h05 HE | Source: Immunovaccine Inc.

Society for Immunotherapy of Cancer (SITC) Recognizes Immunovaccine Researchers with Journal for ImmunoTherapy of Cancer (JITC) “Best Basic Science Paper Award”

HALIFAX, Nova Scotia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Society for Immunotherapy of...

Page précédente

Page suivante